US9872898B2ActiveUtilityA1

Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome

88
Assignee: OHIO STATE INNOVATION FOUNDATIONPriority: Apr 24, 2012Filed: Oct 3, 2016Granted: Jan 23, 2018
Est. expiryApr 24, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:Renukaradhya J. GourapuraVarun DwivediBasavaraj S. BinjawadagiJordi Torrelles
A61K 35/74A61K 9/5153A61K 2039/5252A61K 39/385C12N 2770/10071A61K 2039/552A61K 2039/5258A61K 2039/6093C12N 7/00C12N 2770/10061A61P 31/14A61K 2039/58A61K 2039/543A61K 2039/55544A61K 35/76C12N 2770/10021A61K 39/12B82Y 5/00C12N 2770/10034A61K 2039/55555A61K 2039/541A61K 39/39A61K 2039/572A61K 2039/6018A61K 2039/55566A61K 2039/6087A61K 2039/57A61K 2039/55594A61K 9/14C12N 2770/10023A61K 2039/545C07K 16/10
88
PatentIndex Score
4
Cited by
215
References
23
Claims

Abstract

Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A composition comprising an inactivated porcine reproductive and respiratory syndrome virus (PRRSV) associated with a nanoparticle, and a  Mycobacterium  lysate adjuvant. 
     
     
       2. The composition of  claim 1 , wherein the adjuvant is a  Mycobacterium vaccae  whole cell lysate. 
     
     
       3. The composition of  claim 1 , wherein the adjuvant is a  Mycobacterium tuberculosis  whole cell lysate. 
     
     
       4. The composition of  claim 1 , wherein the adjuvant is a  Mycobacterium smegmatis  whole cell lysate. 
     
     
       5. The composition of  claim 1 , wherein the nanoparticle is immunogenic. 
     
     
       6. The composition of  claim 1 , wherein the nanoparticle is conjugated with the inactivated PRRSV. 
     
     
       7. The composition of  claim 1 , wherein the inactivated PRRSV is entrapped within the nanoparticle by a water/oil/water emulsion method. 
     
     
       8. The composition of  claim 1 , wherein the nanoparticle comprises poly(lactide co-glycolide) (PLGA). 
     
     
       9. The composition of  claim 8 , wherein the PLGA is 50/50 PLGA. 
     
     
       10. The composition of  claim 1 , wherein the nanoparticle comprises chitosin. 
     
     
       11. The composition of  claim 8 , in a ratio of about 180 mg of PLGA to about 5 mg of inactivated PRRSV. 
     
     
       12. The composition of  claim 1 , wherein the inactivated PRRSV is the MN184 strain of PRRSV. 
     
     
       13. The composition of  claim 1 , wherein the inactivated PRRSV is inactivated by UV light. 
     
     
       14. A vaccine comprising a composition of  claim 1  in a carrier. 
     
     
       15. A method of eliciting an immune response against PRRSV in a pig comprising administering to said pig the vaccine of  claim 14 . 
     
     
       16. The method of  claim 15 , wherein the immune response is protective against PRRSV infection. 
     
     
       17. A method of reducing reproductive or respiratory failure in a pig comprising administering to said pig the vaccine of  claim 14 . 
     
     
       18. A method of stimulating an immune response in a pig comprising: administering to said pig the vaccine of  claim 14 . 
     
     
       19. The method of  claim 15 , wherein the vaccine is administered at a dose of between 100 ug/pig and 500 ug/pig. 
     
     
       20. The method of  claim 15 , wherein the composition or vaccine is administered in a single dose. 
     
     
       21. The method of  claim 15 , wherein the vaccine is administered in two doses. 
     
     
       22. The method of  claim 21 , wherein the two doses are administered at about two week intervals. 
     
     
       23. The method of  claim 15 , wherein the vaccine is administered intranasally.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.